Chilton Janice A, Rasmus Monica L, Lytton Jay, Kaplan Charles D, Jones Lovell A, Hurd Thelma C
Pharmacy Administration and Administrative Health Sciences, Texas Southern University, Houston, TX, United States.
Adult Mental Health and Wellnes, University of Southern California, Los Angeles, CA, United States.
Front Oncol. 2018 Aug 10;8:300. doi: 10.3389/fonc.2018.00300. eCollection 2018.
Trust exerts a multidimensional influence at the interpersonal level in the clinical trials setting. Trust and distrust are dynamic states that are impacted, either positively or negatively, with each participant-clinical trials team interaction. Currently, accepted models of trust posit that trust and distrust coexist and their effects on engagement and retention in clinical trials are mediated by ambivalence. While understanding of trust has been informed by a robust body of work, the role of distrust and ambivalence in the trust building process are less well understood. Furthermore, the role of ambivalence and its relationship to trust and distrust in the clinical trials and oncology settings are not known. Ambivalence is a normal and uncomfortable state in the complex decision making process that characterizes the recruitment and active treatment phases of the clinical trials experience. The current review was conducted to understand the constructs of ambivalence as a mediator of trust and distrust among vulnerable, minority participants through different stages of the oncology clinical trials continuum, its triggers and the contextual factors that might influence it in the setting of minority participation in oncology clinical trials. In addition, the researchers have sought to link theory to clinical intervention by investigating the feasibility and role of Motivational Interviewing in different stages of the clinical trials continuum. Findings suggest that ambivalence can be processed and managed to enable a participant to generate a response to their ambivalence. Thus, recognizing and managing triggers of ambivalence, which include, contradictory goals, role conflicts, membership dualities, and supporting participants through the process of reducing ambivalence is critical to successfully managing trust. Contextual factors related to the totality of one's previous health-care experience, specifically among the marginalized or vulnerable, can contribute to interpersonal ambivalence. In addition, changes in information gathering as a moderator of interpersonal ambivalence may have enormous implications for gathering, assessing, and accepting health information. Finally, motivational Interviewing has widespread applications in healthcare settings, which includes enabling participants to navigate ambivalence in shared-decision making with their clinician, as well as executing changes in participant behavior. Ultimately, the Integrated Model of Trust can incorporate the role of therapeutic techniques like Motivational Interviewing in different stages of the clinical trials continuum. Ambivalence is a key component of clinical trial participation; like trust, ambivalence can be managed and plays a major role in the management of trust in interpersonal relationships over time. The management of ambivalence may play a major role in increasing clinical trial participation particularly among the marginalized or the vulnerable, who may be more susceptible to feelings of ambivalence.
在临床试验环境中,信任在人际层面发挥着多维度的影响。信任和不信任是动态状态,在每个参与者与临床试验团队的互动中,它们会受到积极或消极的影响。目前,公认的信任模型认为信任和不信任并存,它们对临床试验参与度和留存率的影响是由矛盾心理介导的。虽然大量研究工作为理解信任提供了依据,但不信任和矛盾心理在信任建立过程中的作用却鲜为人知。此外,矛盾心理及其与临床试验和肿瘤学环境中信任与不信任的关系也尚不明确。矛盾心理是复杂决策过程中的一种正常且令人不适的状态,它贯穿于临床试验经历的招募和积极治疗阶段。本次综述旨在通过肿瘤学临床试验连续过程的不同阶段,了解矛盾心理作为弱势群体、少数族裔参与者中信任与不信任的调解因素的构成、其触发因素以及在少数族裔参与肿瘤学临床试验背景下可能影响它的情境因素。此外,研究人员试图通过研究动机性访谈在临床试验连续过程不同阶段的可行性和作用,将理论与临床干预联系起来。研究结果表明,矛盾心理可以得到处理和管理,使参与者能够对自己的矛盾心理做出反应。因此,识别和管理矛盾心理的触发因素,包括相互矛盾的目标、角色冲突、成员身份的双重性,并在减少矛盾心理的过程中支持参与者,对于成功管理信任至关重要。与个人以往整体医疗保健经历相关的情境因素,尤其是在边缘化或弱势群体中,可能会导致人际矛盾心理。此外,作为人际矛盾心理调节因素的信息收集变化,可能对收集、评估和接受健康信息产生巨大影响。最后,动机性访谈在医疗保健环境中有广泛应用,包括使参与者在与临床医生共同决策时应对矛盾心理,以及促使参与者行为发生改变。最终,信任综合模型可以纳入动机性访谈等治疗技术在临床试验连续过程不同阶段的作用。矛盾心理是临床试验参与的关键组成部分;与信任一样,矛盾心理可以得到管理,并且随着时间推移在人际关系中信任管理方面发挥重要作用。矛盾心理的管理可能在增加临床试验参与度方面发挥重要作用,特别是在边缘化或弱势群体中,他们可能更容易产生矛盾心理。